Optimizing the in vitro production of immunomodulatory cells for the induction of tolerance in solid organ transplantation
Treating responder and irradiated stimulator PBMC with RBC lysis buffer before co-culture in TexMACS medium supplemented with 1% autologous plasma and 40 μg belatacept per million cells for 14 days produces DSIMC which meet established quality criteria. The protocol is currently currently under evaluation in a clinical study.
Authors
- Bo‐Göran Ericzon (ORCID: https://orcid.org/0000-0001-5604-2427)
- Nils Ågren (ORCID: https://orcid.org/0000-0002-1220-5375)
- Makiko Kumagai‐Braesch (ORCID: https://orcid.org/0000-0001-6011-0744)
- Ming Yao (ORCID: https://orcid.org/0000-0001-7974-0631)
- Keyvan Habibi
- Carl Skantze
Institutions
- Karolinska Institutet (SE)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1371/journal.pone.0333356
- Primary Topic
- Xenotransplantation and immune response
- Type
- article
- Field-Weighted Citation Impact
- 0.00